EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Tumor-cell HMGB1 restrains CD8+ T-cell immunity during conventional fractionated radiotherapy

Chen Chen, Jiahong Shi, Peihai Cao, Juan Bai, Yutiantian Lei, Mengdi Huang, Mingjun Si, Ruiying Wang, Tingting Lv, Rui Jia, Qiuyu Mu, Dingge Jiang und 2 weitere

Cancer Letters · 2026

DOI: 10.1016/j.canlet.2026.218843 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Chen Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710004, China; Department of Pathogen …. Hauptthemen laut MEDLINE: HMGB1 Protein, CD8-Positive T-Lymphocytes, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Xi'an Jiaotong University, Shaanxi Province Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Conventional fractionated radiotherapy (CFRT) remains a mainstay for many solid tumors, yet it often fails to elicit durable anti-tumor immunity. How CFRT engages tumor-cell programs to shape the immune microenvironment and determine therapeutic outcome remains unclear. Here we show in preclinical mouse models that CFRT is associated with increased tumor-cell HMGB1 relative to stereotactic body radiotherapy (SBRT), and that loss of tumor-cell HMGB1 eliminates the efficacy gap between the regimens. HMGB1 deficiency markedly restrains tumor progression under CFRT in immunocompetent, but not immunodeficient, hosts, accompanied by increased intratumoral CD8+ T cells and effector function. In esophageal squamous cell carcinoma (ESCC) specimens from patients receiving CFRT plus platinum-based chemotherapy, tumor-cell HMGB1 increases after treatment, and elevated pretreatment HMGB1 is associated with poor treatment response, reduced post-treatment CD8+ T-cell infiltration, and adverse outcomes. Mechanistically, HMGB1 restrains CFRT-induced CD8+ T-cell immunity through two convergent arms: CCL2-CCR2-dependent accumulation of suppressive monocytes and FUT8-linked regulation of PD-L1 fucosylation in tumor cells. TCF4 is linked to HMGB1-dependent induction of CCL2 and FUT8. Blocking CCL2 or inhibiting PD-L1 fucosylation restores CD8+ T-cell effector function and enhances CFRT efficacy, alone or in combination with anti-PD-1 therapy. Together, these findings identify a tumor-cell HMGB1 program that underpins CFRT-associated immune suppression and nominate actionable targets to improve CFRT-immunotherapy combinations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HMGB1 ProteinCD8-Positive T-LymphocytesEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaAnimalsHumansMiceDose Fractionation, RadiationTumor MicroenvironmentCell Line, TumorFemaleMice, Inbred C57BLLymphocytes, Tumor-Infiltrating

Stichwörter der Autor:innen

CD8(+) T cellsESCCHMGB1ImmunosuppressionRadiotherapy

Substanzen

HMGB1 ProteinHMGB1 protein, humanHMGB1 protein, mouse

Autor:innen und Institutionen

  • Department of Radiation Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710004, China; Department of Pathogen Microbiology and Immunology, School of Basic Medical Sciences, Xi'an J…
  • Department of Pathogen Microbiology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China.
  • Department of Anesthesiology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.
  • Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.
  • Department of Pathogen Microbiology and Immunology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China; Department of Radiation Oncology, The First Affiliate…
  • Department of Radiation Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710004, China. Electronic address: huangshan2016@xjtu.edu.cn.

Förderung

  • Xi'an Jiaotong University
  • Shaanxi Province Natural Science Foundation
  • National Natural Science Foundation of China
  • Shaanxi Province Key Research and Development Projects

Zitieren

APA

Chen, C., Shi, J., Cao, P., Bai, J., Lei, Y., Huang, M., Si, M., Wang, R., Lv, T., Jia, R., Mu, Q., Jiang, D., Hou, Y., & Huang, S. (2026). Tumor-cell HMGB1 restrains CD8+ T-cell immunity during conventional fractionated radiotherapy. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218843

Vancouver

Chen C, Shi J, Cao P, Bai J, Lei Y, Huang M, et al. Tumor-cell HMGB1 restrains CD8+ T-cell immunity during conventional fractionated radiotherapy. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218843

BibTeX
@article{Chen2026,
  author = {Chen, Chen and Shi, Jiahong and Cao, Peihai and Bai, Juan and Lei, Yutiantian and Huang, Mengdi and Si, Mingjun and Wang, Ruiying and Lv, Tingting and Jia, Rui and Mu, Qiuyu and Jiang, Dingge and Hou, Yuzhu and Huang, Shan},
  title = {Tumor-cell HMGB1 restrains CD8+ T-cell immunity during conventional fractionated radiotherapy},
  journal = {Cancer Letters},
  year = {2026},
  doi = {10.1016/j.canlet.2026.218843}
}
Kostenlos starten →